Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Executive Summary
Novartis' decision to expand its sales force by 1,000 reps in the U.S. - in the face of cuts by many of its competitors - reflects the growth potential of the firm's product portfolio and the strength of its pipeline, Pharmaceuticals CEO Thomas Ebeling said